Cargando…
Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis
Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA patient...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770905/ https://www.ncbi.nlm.nih.gov/pubmed/31540528 http://dx.doi.org/10.3390/ijms20184633 |
_version_ | 1783455592368570368 |
---|---|
author | Hoffman, Elinoar Rahat, Michal A. Feld, Joy Elias, Muna Rosner, Itzhak Kaly, Lisa Lavie, Idit Gazitt, Tal Zisman, Devy |
author_facet | Hoffman, Elinoar Rahat, Michal A. Feld, Joy Elias, Muna Rosner, Itzhak Kaly, Lisa Lavie, Idit Gazitt, Tal Zisman, Devy |
author_sort | Hoffman, Elinoar |
collection | PubMed |
description | Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA patients. Height, weight, disease activity scores, lipid profile and atherogenic indices (AI), leptin, adiponectin, resistin, interleukin-6, and high-sensitivity C-reactive protein (CRP) were measured before and four months after initiation of TCZ in 40 RA patients and 40 healthy controls. Following TCZ treatment, total cholesterol, high density lipoprotein (HDL), and triglycerides were significantly elevated, but no significant changes in weight, body mass index (BMI), low density lipoprotein (LDL), and AI were observed. Compared with controls, significantly higher adiponectin levels were measured in the RA group at baseline. Following TCZ treatment, resistin levels and the leptin-to-adiponectin ratio increased, adiponectin levels decreased, and leptin levels remained unchanged. No correlation was found between the change in adipokine serum levels and changes in the disease activity indices, nor the lipid profile. In conclusion, the changes observed suggest a protective role for TCZ on the metabolic and cardiovascular burden associated with RA, but does not provide a mechanistic explanation for this phenomenon. |
format | Online Article Text |
id | pubmed-6770905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67709052019-10-30 Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis Hoffman, Elinoar Rahat, Michal A. Feld, Joy Elias, Muna Rosner, Itzhak Kaly, Lisa Lavie, Idit Gazitt, Tal Zisman, Devy Int J Mol Sci Article Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA patients. Height, weight, disease activity scores, lipid profile and atherogenic indices (AI), leptin, adiponectin, resistin, interleukin-6, and high-sensitivity C-reactive protein (CRP) were measured before and four months after initiation of TCZ in 40 RA patients and 40 healthy controls. Following TCZ treatment, total cholesterol, high density lipoprotein (HDL), and triglycerides were significantly elevated, but no significant changes in weight, body mass index (BMI), low density lipoprotein (LDL), and AI were observed. Compared with controls, significantly higher adiponectin levels were measured in the RA group at baseline. Following TCZ treatment, resistin levels and the leptin-to-adiponectin ratio increased, adiponectin levels decreased, and leptin levels remained unchanged. No correlation was found between the change in adipokine serum levels and changes in the disease activity indices, nor the lipid profile. In conclusion, the changes observed suggest a protective role for TCZ on the metabolic and cardiovascular burden associated with RA, but does not provide a mechanistic explanation for this phenomenon. MDPI 2019-09-18 /pmc/articles/PMC6770905/ /pubmed/31540528 http://dx.doi.org/10.3390/ijms20184633 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hoffman, Elinoar Rahat, Michal A. Feld, Joy Elias, Muna Rosner, Itzhak Kaly, Lisa Lavie, Idit Gazitt, Tal Zisman, Devy Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis |
title | Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis |
title_full | Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis |
title_fullStr | Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis |
title_full_unstemmed | Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis |
title_short | Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis |
title_sort | effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770905/ https://www.ncbi.nlm.nih.gov/pubmed/31540528 http://dx.doi.org/10.3390/ijms20184633 |
work_keys_str_mv | AT hoffmanelinoar effectsoftocilizumabanantiinterleukin6receptorantibodyonserumlipidandadipokinelevelsinpatientswithrheumatoidarthritis AT rahatmichala effectsoftocilizumabanantiinterleukin6receptorantibodyonserumlipidandadipokinelevelsinpatientswithrheumatoidarthritis AT feldjoy effectsoftocilizumabanantiinterleukin6receptorantibodyonserumlipidandadipokinelevelsinpatientswithrheumatoidarthritis AT eliasmuna effectsoftocilizumabanantiinterleukin6receptorantibodyonserumlipidandadipokinelevelsinpatientswithrheumatoidarthritis AT rosneritzhak effectsoftocilizumabanantiinterleukin6receptorantibodyonserumlipidandadipokinelevelsinpatientswithrheumatoidarthritis AT kalylisa effectsoftocilizumabanantiinterleukin6receptorantibodyonserumlipidandadipokinelevelsinpatientswithrheumatoidarthritis AT lavieidit effectsoftocilizumabanantiinterleukin6receptorantibodyonserumlipidandadipokinelevelsinpatientswithrheumatoidarthritis AT gazitttal effectsoftocilizumabanantiinterleukin6receptorantibodyonserumlipidandadipokinelevelsinpatientswithrheumatoidarthritis AT zismandevy effectsoftocilizumabanantiinterleukin6receptorantibodyonserumlipidandadipokinelevelsinpatientswithrheumatoidarthritis |